Article

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa

2022-09-10

Abstract excerpt

<h4>Background</h4> Respiratory syncytial virus (RSV) causes a substantial burden of acute lower respiratory infection in children under 5 years, particularly in low- and middle-income countries (LMICs). Maternal vaccine (MV) and next-generation monoclonal antibody (mAb) candidates have been shown to reduce RSV disease in infants in phase III clinical trials. The cost-effectiveness of these biologics has been esti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 31c06d0e-74cd-5897-b60c-5d0ee4e885ee
DOI: 10.1101/2022.09.09.22279780

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South AfricaDOI 10.1101/2022.09.09.22279780Read

The burden of RSV-associated illness in children aged <5 years, South Africa, 2011 to 2016Semantic proximity Read

Cost-effectiveness of the next generation of RSV intervention strategiesSemantic proximity Read

Cost-effectiveness of respiratory syncytial virus vaccination for older adults: a modelling analysisSemantic proximity Read

Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa DataSemantic proximity Read

The landscape of paediatric infectious disease exposure in a rural sub-Saharan Africa setting in Kilifi, Kenya: longitudinal serological analysis over two decades and priorities for future vaccine developmentSemantic proximity Read

Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in KenyaSemantic proximity Read

The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2Semantic proximity Read

Clinical and economic burden of Respiratory Syncytial Virus in children aged 0-5 years in ItalySemantic proximity Read

Study protocol: Effectiveness of the maternal RSVpreF vaccine by virus typeSemantic proximity Read

Economic Burden and Return on Investment of Immunization Programs in Saudi Arabia: A Health Economic EvaluationSemantic proximity Read

Modelling the transmission dynamics of RSV and the impact of routine vaccinationSemantic proximity Read

Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention—A WAidid Consensus DocumentSemantic proximity Read